Background: Women with inflammatory rheumatic and musculoskeletal disease (iRMD) face unique challenges during preconception, pregnancy, and lactation. In 2024, a specialised consultation service was developed and implemented at the tertiary rheumatology centre of the Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany, to address these specific needs. Methods: Demographic characteristics, disease- and treatment-related data, reproductive status, referring physician, reasons for consultation, and recommendations for disease management were collected between 1 January 2024 and 3 April 2025. Results: Overall, 57 patients were included; the mean age was 33.3 ± 4.4 years and the mean disease duration was 6.3 ± 4.8 years. Almost all patients (94.7%) had a confirmed diagnosis of an iRMD. 57.9% were planning a pregnancy, 40.4% were pregnant, and 1.8% were breastfeeding. At baseline, 21.8% were receiving csDMARDs and 50.9% were receiving bDMARDs. Glucocorticoid use was documented in 16.1%. Patients were referred by rheumatologists (35.7%), the in-house outpatient clinic (37.5%), general practitioners (14.3%), gynaecologists (10.7%), and the in-house inpatient clinic (1.8%). The most frequent reasons for consultation were patient concerns regarding pregnancy and medication safety. Consultation reasons differed descriptively between patients in the preconception period and pregnant patients; however, these exploratory differences should be interpreted with caution. Recommendations made during consultation included modification of DMARD therapy (35.1%), initiation of fetal bradycardia screening (19.3%), and preeclampsia prophylaxis (8.8%). Conclusion: A dedicated reproductive rheumatology consultation service provides structured support for women with iRMDs throughout preconception, pregnancy, and lactation. Medication adjustments and targeted preventive measures were recommended for more than one-third of patients, highlighting the potential value of preconception referral and specialized reproductive rheumatology consultation. Clinical trial number: Not applicable.